DK0941315T3 - Fusionsproteiner indeholdende stressproteiner til induktion af immunreaktioner - Google Patents

Fusionsproteiner indeholdende stressproteiner til induktion af immunreaktioner

Info

Publication number
DK0941315T3
DK0941315T3 DK97945684T DK97945684T DK0941315T3 DK 0941315 T3 DK0941315 T3 DK 0941315T3 DK 97945684 T DK97945684 T DK 97945684T DK 97945684 T DK97945684 T DK 97945684T DK 0941315 T3 DK0941315 T3 DK 0941315T3
Authority
DK
Denmark
Prior art keywords
antigen
relates
vaccines
induce
immune responses
Prior art date
Application number
DK97945684T
Other languages
Danish (da)
English (en)
Inventor
Lee Mizzen
Lawrence S D Anthony
Original Assignee
Stressgen Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stressgen Biotechnologies Corp filed Critical Stressgen Biotechnologies Corp
Application granted granted Critical
Publication of DK0941315T3 publication Critical patent/DK0941315T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK97945684T 1996-11-26 1997-11-25 Fusionsproteiner indeholdende stressproteiner til induktion af immunreaktioner DK0941315T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75662196A 1996-11-26 1996-11-26

Publications (1)

Publication Number Publication Date
DK0941315T3 true DK0941315T3 (da) 2006-05-15

Family

ID=25044309

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97945684T DK0941315T3 (da) 1996-11-26 1997-11-25 Fusionsproteiner indeholdende stressproteiner til induktion af immunreaktioner

Country Status (11)

Country Link
EP (1) EP0941315B1 (pt)
JP (2) JP4484969B2 (pt)
AT (1) ATE318899T1 (pt)
AU (1) AU736318B2 (pt)
CA (1) CA2272536A1 (pt)
DE (1) DE69735376T2 (pt)
DK (1) DK0941315T3 (pt)
ES (1) ES2258796T3 (pt)
HK (1) HK1022715A1 (pt)
PT (1) PT941315E (pt)
WO (1) WO1998023735A1 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510756A (ja) 1993-06-04 1996-11-12 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ストレス蛋白質とその使用
WO1997006828A1 (en) 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious diseases and compositions useful in same
US6761892B1 (en) 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
BE1011033A6 (fr) 1997-03-05 1999-04-06 Univ Bruxelles Composition pharmaceutique et/ou alimentaire pour le traitement de pathologies liees a un rejet de greffe, une reaction allergique ou auto-immune ou du cancer.
US6709672B2 (en) 1997-03-05 2004-03-23 Biotech Tools S.A. Pharmaceutical or food composition for treating pathologies associated with graft rejection or an allergic or autoimmune reaction
JP4198315B2 (ja) 1997-08-05 2008-12-17 ヌベンタ バイオファーマスティカル コーポレイション Hpv抗原およびストレスタンパク質またはこれらのタンパク質の発現が可能な発現ベクターを含む組成物によって誘起されるhpv抗原に対する免疫応答
US7731972B1 (en) 2000-02-04 2010-06-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
EP0996717B1 (en) 1997-08-05 2005-12-07 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunoprotective influenza antigen and its use in vaccination
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
CN1324243A (zh) * 1998-01-23 2001-11-28 国家犹太医疗及研究中心 使用热激蛋白治疗炎性疾病的方法
EP2295065B1 (en) 1998-02-20 2013-10-09 The University of Miami Modified heat shock protein-antigenic peptide complex
CA2352286C (en) * 1998-11-24 2011-07-12 Bristol-Myers Squibb Company Intracellular targeted delivery of compounds by 70 kd heat shock protein
CN1367875A (zh) 1999-07-08 2002-09-04 斯特思吉生物技术公司 活体外th1一样反应的诱导方法
AUPQ233799A0 (en) 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
US20020039583A1 (en) * 1999-09-30 2002-04-04 Subjeck John R. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
WO2001023421A2 (en) 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US7378096B2 (en) 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
CA2388045C (en) * 1999-10-20 2014-02-11 Tzyy-Choou Wu Nucleic acid immunogenic compositions encoding hsp-antigen chimera
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
EP1253939B1 (en) 2000-01-14 2009-08-05 Whitehead Institute For Biomedical Research In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent
ATE326236T1 (de) 2000-06-26 2006-06-15 Stressgen Biotechnologies Corp Hpv-e7 zur behandlung von menschlichem papillomavirus
ES2454640T3 (es) 2000-08-03 2014-04-11 Johns Hopkins University Vacuna molecular que lleva unida un polipéptido de chaperona del retículo endoplasmático a un antígeno
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
WO2002062959A2 (en) 2001-02-05 2002-08-15 Stressgen Biotechnologies Corp. Hepatitis b virus treatment
EP1536006B1 (en) 2002-08-30 2011-08-24 Medinet Co., Ltd. Cancer antigens and utilization thereof
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
US7420037B2 (en) 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
US7309491B2 (en) 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
WO2004098526A2 (en) 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
AU2005322960A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
JP2008527009A (ja) 2005-01-19 2008-07-24 バクシネート コーポレーション 病原体関連分子パターンおよび抗原を含む組成物ならびに免疫応答を刺激するためのそれらの使用
DK1968632T3 (da) 2005-12-06 2012-07-16 Yeda Res & Dev Forbedret influenzavaccine
AU2007224034B2 (en) 2006-03-07 2012-03-29 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
US20100143393A1 (en) * 2006-05-11 2010-06-10 Gale Smith Novel influenza m2 vaccines
EP2044224A4 (en) * 2006-07-27 2011-04-13 Ligocyte Pharmaceuticals Inc CHIMERIC VIRUS TYPE PARTICLES
AU2007345768B2 (en) * 2006-07-27 2013-08-01 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
NZ579262A (en) * 2007-02-23 2012-04-27 Baylor Res Inst Therapeutic applications of activation of human antigen-presenting cells through dectin-1
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
WO2009117116A2 (en) 2008-03-20 2009-09-24 University Of Miami Heat shock protein gp96 vaccination and methods of using same
CN102753582A (zh) 2009-11-03 2012-10-24 莱戈赛特医药股份有限公司 嵌合RSV-F多肽、和慢病毒或α-反转录病毒GAG基VLP
US8685406B2 (en) * 2009-11-13 2014-04-01 The Board Of Regents Of The University Of Texas System Compositions of and method of using heat shock protein peptides
CN103687616A (zh) * 2011-07-21 2014-03-26 生物技术工具公司 Dnak制剂
WO2016127015A1 (en) 2015-02-06 2016-08-11 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
WO2018071405A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
KR101805430B1 (ko) 2017-04-26 2017-12-06 (주)넥스젠바이오텍 항산화 활성 및 피부 세포 증식 효과가 증가한 열 충격 단백질의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물
CN118076389A (zh) * 2021-08-30 2024-05-24 日环科学株式会社 免疫赋活制剂及含有该免疫赋活制剂的化妆品、食品、饲料添加剂、准药品

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102687A (en) * 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
JPH08510756A (ja) * 1993-06-04 1996-11-12 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ストレス蛋白質とその使用
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
WO1997006828A1 (en) * 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious diseases and compositions useful in same
WO1997026910A2 (de) * 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren

Also Published As

Publication number Publication date
AU736318B2 (en) 2001-07-26
EP0941315B1 (en) 2006-03-01
HK1022715A1 (en) 2000-08-18
EP0941315A1 (en) 1999-09-15
AU5112098A (en) 1998-06-22
JP2008214360A (ja) 2008-09-18
CA2272536A1 (en) 1998-06-04
ES2258796T3 (es) 2006-09-01
DE69735376D1 (de) 2006-04-27
DE69735376T2 (de) 2006-12-14
PT941315E (pt) 2006-06-30
WO1998023735A1 (en) 1998-06-04
JP4484969B2 (ja) 2010-06-16
ATE318899T1 (de) 2006-03-15
JP2001504702A (ja) 2001-04-10

Similar Documents

Publication Publication Date Title
DK0941315T3 (da) Fusionsproteiner indeholdende stressproteiner til induktion af immunreaktioner
DK0587780T4 (da) Smitstof, som forårsager Mystery Swine Disease,vaccinepræparater og diagnostiske sæt
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
CY1107570T1 (el) Ανοσογονικα πολυπεπτιδια κωδικοποιουμενα απο μινιγονιδια mage και οι χρησεις τους
DK1659179T3 (da) Tumor-associerede antigenderivater fra MAGE-familien og nucleinsyresekvenser kodende for dem anvendt til fremstilling af fusionsproteiner og sammensætninger til vaccination
ATE468127T1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
WO2007016185A3 (en) Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
BRPI0815578B8 (pt) peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina
EP2290091A3 (en) Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
NO20081043L (no) Vaksine for fisk
ATE389397T1 (de) Adjuvante zusammensetzungen
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
BR9907883A (pt) Composição de vacina, processo para eliciar uma resposta imune a um antìgeno de vìrus de herpes simplex, e, composição imunogênica
WO2023147092A3 (en) Coronavirus vaccine
DK1397380T3 (da) Multipelt antigent peptid, der udviser flere kopier af en epitop af et plaquedannende polypeptid, og fremgangmåder til anvendelse deraf
WO2004078099A3 (en) Compositions and methods for the generation of protective immune response against malaria
ATE319833T1 (de) Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
DE69739233D1 (de) Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff
DK1499349T3 (da) Rekombinante hybrid-allergenkonstrukter med reduceret allergenitet, der bibeholder det naterulige allergens immunogenitet
BRPI0309787E2 (pt) Polipeptídeo isolado, composição de vacina anti-carrapato de espécies múltiplas, molécula de cdna isolada, vetor de expressão, célula isolada, vacina anti-carrapato de espécie múltipla, e, método de induzir uma resposta imune em um mamífero contra a infestação de carrapato de espécie múltipla e seus patógenos associados
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
BRPI0604365A (pt) polipeptìdeo isolado, composição de vacina anti-carrapato de múltiplas espécies, e, uso dos mesmos
MXPA03010527A (es) Composicion de vacuna.